Type of security: Stock
Sector: Health Care
Industry: Biotechnology: Biological Products (No Diagnostic Substances)
The data is delayed by 15 minutes.
Description: bluebird bio, Inc., a clinical-stage biotechnology company, focuses on developing gene therapies for severe genetic and orphan diseases. The company?s advanced product candidate is Lenti-D, which is in phase II/III studies for the treatment of childhood cerebral adrenoleukodystrophy, a rare, hereditary neurological disorder affecting young boys; and LentiGlobin that is in phase I/II studies for the treatment of beta-thalassemia major and severe sickle cell disease in France, as well as a second phase I/II studies with LentiGlobin for the treatment of beta-thalassemia major in the United States. bluebird bio, Inc. has a strategic collaboration with Celgene Corporation to discover, develop, and commercialize disease-altering gene therapies in oncology. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was founded in 1992 and is headquartered in Cambridge, Massachusetts.
See how to gain 20% in 14 sec with TrendsInvesting
|Shares Outstanding||EPS||-7.22||EPS Growth - 4 Quarters||EPS Growth - Q/Q|
|EPS Growth - Y/Y||Sales Growth - 4 Quarters||0.14%||Sales Growth - Q/Q||-0.66%||P/E||-15.06|
|P/E To EPS Growth||P/S||P/BV||Price/Cash Per Share|
|Price/Free Cash Flow||ROA||-11.78%||ROE||-13.25%||ROI|
|Current Ratio||8.11||Quick Ratio||Long Term Debt/Equity||Debt Ratio||0.09|
|Gross Margin||Operating Margin||-294.47%||Net Profit Margin||-247.3%||Dividend Payout Ratio|
|Cash From Financing Activities||2.46 M||Cash From Investing Activities||-192.98 M||Cash From Operating Activities||-24.16 M||Gross Profit|
|Net Profit||-24.79 M||Operating Profit||-24.93 M||Total Assets||533.82 M||Total Current Assets||340.84 M|
|Total Current Liabilities||42.01 M||Total Debt||Total Liabilities||59.32 M||Total Revenue||6.34 M|
|High 52 week||162.45||Low 52 week||85.49||Last close||89.55||Last change||0.87%|
|RSI||22.21||Average true range||4.12||Beta||1.73||Volume||513.89 K|
|Simple moving average 20 days||-5.15%||Simple moving average 50 days||-13.63%||Simple moving average 200 days||-29.27%|
|Performance Week||0.95%||Performance Month||-16.2%||Performance Quart||-35.78%||Performance Half||-41.86%|
|Performance Year||-28.98%||Performance Year-to-date||-9.73%||Volatility daily||2.57%||Volatility weekly||5.75%|
|Volatility monthly||11.78%||Volatility yearly||40.8%||Relative Volume||135.56%||Average Volume||645.24 K|
|New High||New Low|
2019-12-06 16:30:40 | Bluebird, Celgene Cancer Therapy Gets Boost From New Study
2019-12-06 09:15:02 | Stocks Rebound and Hang Onto Recent Gains
2019-12-03 08:52:01 | Are Options Traders Betting on a Big Move in bluebird BLUE Stock?
2019-11-27 03:28:08 | Global Blood's GBT Oxbryta Secures FDA Approval for SCD
2019-11-26 09:19:00 | Bluebird Bio Stock Is Rising as Analyst Cites Room for Gains
2019-11-19 10:46:45 | CRISPR Therapeutics stock jumps on early gene editing data
2019-11-18 09:36:02 | Novartis Receives FDA Nod for Adakveo in Sickle Cell Disease
2019-11-12 07:00:00 | bluebird bio and Forty Seven Announce a Research Collaboration to Study an All Antibody Conditioning Regimen for Use in Combination with Autologous Lentiviral Vector Hematopoietic Stem Cell Gene Therapy
2019-11-08 14:20:35 | FDA approves Acceleron's blood disorder drug ahead of schedule
2019-11-07 06:08:01 | These 36 Mass. firms made Deloitte's Technology Fast 500
2019-11-03 08:03:00 | Companies Like bluebird bio NASDAQ:BLUE Are In A Position To Invest In Growth
2019-10-31 17:35:09 | Bluebird Bio BLUE Reports Q3 Loss, Misses Revenue Estimates
2019-10-23 16:30:00 | bluebird bio Announces Transition of Chief Strategy Officer Jeffrey T. Walsh
2019-10-18 11:22:28 | New Gilead CFO: Let's Make a Deal
2019-10-17 10:30:27 | What Does A Double Bottom Base Look Like? This Top Biotech Stock Formed A Great One
2019-10-15 11:01:11 | Is bluebird bio Inc BLUE Going To Burn These Hedge Funds ?
2019-10-11 12:49:04 | Jazz Starts CAR T-cell Linked Neurotoxicity Study Enrollment
2019-10-10 11:17:03 | bluebird Inks Genome Editing Research Deal With Novo Nordisk
2019-10-03 15:02:17 | 3 Cancer-Fighting Drug Stocks to Buy Right Now
2019-10-01 13:48:06 | Stifel Bullish On Iovance And Fate Therapeutics, Neutral On Bluebird Bio
2019-10-01 05:52:26 | LabCentral gets state, private funds for new biomanufacturing lab space
2019-09-27 07:00:00 | bluebird bio Appoints William R. Sellers, M.D. to Board of Directors
2019-09-19 09:57:05 | Is There An Opportunity With bluebird bio, Inc.'s NASDAQ:BLUE 48% Undervaluation?
2019-09-18 09:25:00 | bluebird bio Presents Updated Data from Phase 2/3 Clinical Study of Lenti-D™ Gene Therapy for Cerebral Adrenoleukodystrophy CALD at the 13th European Pediatric Neurology Society EPNS Congress
2019-09-09 13:33:00 | Here's Why bluebird bio Fell 21.3% in August
2019-09-06 11:53:03 | FDA Grants Priority Review to Global Blood's SCD Candidate
2019-08-31 09:31:01 | Bluebird BLUE Down 19.4% Since Last Earnings Report: Can It Rebound?
2019-08-22 16:05:00 | bluebird bio Announces Investor Events in September
2019-08-22 02:18:27 | Massachusetts-based biotech company opens office in Eastlake neighborhood Photos
2019-08-16 06:20:45 | Gene therapies to test FDA's approach to regulating drugs after launch, experts say
2019-08-12 16:16:47 | Why This Biotech's $1.8 Million Gene Therapy Could Be A 'Slow Mover'
2019-08-12 10:30:00 | Bluebird Bio Stock Down as Analyst Raises Worries About Zynteglo Launch
2019-08-12 07:38:00 | Bluebird Bio Drops Following William Blair Downgrade
2019-08-08 10:25:53 | Did bluebird bio, Inc. NASDAQ:BLUE Insiders Sell Shares?
2019-08-07 17:30:00 | bluebird bio Prepares for Launch
2019-08-02 11:12:03 | bluebird's BLUE Loss Wider Than Expected, Revenues Beat
2019-08-01 19:45:11 | Bluebird Bio BLUE Reports Q2 Loss, Tops Revenue Estimates
2019-07-15 14:46:29 | Biotech investors Wellington, RA Capital’s new funds top $700 million
2019-07-10 05:43:59 | JP Morgan: 2 Gene Therapy Stocks to Buy Now
2019-07-09 13:58:30 | 5 Immunotherapy Stocks to Keep a Close Eye On
2019-07-07 12:13:00 | Is bluebird bio a Buy?